Description

Factor VIII:C Polyclonal Antibody – Affinity Purified – FITC Conjugated

Affinity’s Factor VIII:C Polyclonal Antibody – Affinity Purified – FITC Conjugated is the highest level of our Fluorescein Isothiocyanate (FITC) Factor VIII:C antibodies.  During the Antigen Affinity Purification process the IgG has had any non-specific immunoglobulin fraction eliminated which enriches the specificity of the remaining immunoglobulin towards the target antigen.  The result is a very high-purity product with a substantially higher titre than whole or purified IgG.  Our Factor VIII:C Polyclonal Antibody – Affinity Purified – FITC Conjugated is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v) and has been conjugated with FITC as an enzyme reporter.  This antibody is generally intended for use as labelled primary antibodies in applications such as immunoassay and immunoblotting.

Product Code: SAF8C-APFTC

Retail Product Size:  0.1mg vial

Host Animal: Sheep Anti-Human Factor VIII:C Polyclonal Antibody – Affinity Purified – FITC Conjugated

Species Cross Reactivity: View Chart

Product Datasheet: Factor VIII F8 Polyclonal Antibody - affinity purified FITC conjugated anti-human sheep IgG

Description of Factor VIII

Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of FVIII ranging in size from 200-280 kDa. The FVIII is stabilized by association with von Willebrand Factor to form a FVIII-vWF complex required for the normal survival of FVIII in vivo (t1/2 of 8-12 hours).

F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, FVIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.

Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of FVIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a FVIII protein that is partially or totally inactive. The production of neutralizing antibodies to FVIII also occurs in 5-20% of Hemophiliacs ^1-3.

References and Review

1. Lollar P, Fay PJ, Fass DN; Factor VIII and Factor VIIIa. Methods in Enzymology, 222, pg 122, 1993.
2. Hoyer, LW, Wyshock EG, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
3. Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. Thromb. Haemostasis. 61:161-165, 1989.